BaseLaunch announces a new partnership with AbbVie
Media release
Basel, Switzerland, 22.05.2024
BaseLaunch announces a new partnership with AbbVie
- Further strengthens BaseLaunch’s global pharma industry partnerships
- 24 early-stage biotech ventures have now been supported by BaseLaunch
- Portfolio companies have raised over US$ 600 million in equity capital
BaseLaunch, the Basel-based biotech venture incubator, today announces that AbbVie has become its newest partner. Through this strategic investment into BaseLaunch, AbbVie gains access to the highest quality life science deal flow in central Europe. By taking a seat on BaseLaunch`s investment board, AbbVie will lend its unique experience in biotech innovation and development of medicines that matter to the incubator. This will greatly add to the venture building capabilities of BaseLaunch.
